These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 25213365)

  • 21. [New aspects in ANCA-associated vasculitides].
    Lamprecht P
    Med Klin (Munich); 2004 Sep; 99(9):518-22. PubMed ID: 15372181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.
    Lenert A; Lenert P
    Drug Des Devel Ther; 2015; 9():333-47. PubMed ID: 25609919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biologic treatment of large-vessel vasculitides.
    Schäfer VS; Zwerina J
    Curr Opin Rheumatol; 2012 Jan; 24(1):31-7. PubMed ID: 22089099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
    Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
    Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biologics in vasculitides: Where do we stand, where do we go from now?
    Pazzola G; Muratore F; Pipitone N; Salvarani C
    Presse Med; 2015 Jun; 44(6 Pt 2):e231-9. PubMed ID: 26024760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab.
    Eriksson P
    J Intern Med; 2005 Jun; 257(6):540-8. PubMed ID: 15910558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [New options in treatment of therapy refractory vasculitis].
    Lamprecht P
    Z Rheumatol; 2003 Apr; 62(2):114-5. PubMed ID: 12820616
    [No Abstract]   [Full Text] [Related]  

  • 28. Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients.
    Wendt M; Gunnarsson I; Bratt J; Bruchfeld A
    Scand J Rheumatol; 2012 Mar; 41(2):116-9. PubMed ID: 22118245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of vasculitis].
    Novak S
    Reumatizam; 2013; 60(2):47-54. PubMed ID: 24979997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New indications for biological therapies.
    Catanoso M; Pipitone N; Magnani L; Boiardi L; Salvarani C
    Intern Emerg Med; 2011 Oct; 6 Suppl 1():1-9. PubMed ID: 22009607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review.
    Bosch X; Guilabert A; Espinosa G; Mirapeix E
    JAMA; 2007 Aug; 298(6):655-69. PubMed ID: 17684188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Safety and efficacy of biologics directed against TNF-alpha and CD20 in the therapy of vasculitis and systemic lupus erythematosus].
    Walker UA; Hasler P
    Ther Umsch; 2008 May; 65(5):303-10. PubMed ID: 18622936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis.
    Keogh KA; Wylam ME; Stone JH; Specks U
    Arthritis Rheum; 2005 Jan; 52(1):262-8. PubMed ID: 15641078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD20-depleting therapy in autoimmune diseases: from basic research to the clinic.
    Perosa F; Prete M; Racanelli V; Dammacco F
    J Intern Med; 2010 Mar; 267(3):260-77. PubMed ID: 20201920
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Diagnosis und therapy of ANCA-associated vasculitis].
    Aries PM; Hellmich B; Gross WL
    Dtsch Med Wochenschr; 2006 Mar; 131(9):443-6. PubMed ID: 16493569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diffuse Alveolar Hemorrhage and Pulmonary Vasculitides: Histopathologic Findings.
    Scapa JV; Fishbein GA; Wallace WD; Fishbein MC
    Semin Respir Crit Care Med; 2018 Aug; 39(4):425-433. PubMed ID: 30404110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting B lymphocytes as therapy for ANCA-associated vasculitis.
    Golbin JM; Specks U
    Rheum Dis Clin North Am; 2007 Nov; 33(4):741-54, v. PubMed ID: 18037114
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antineutrophil cytoplasmic antibody-associated vasculitides and respiratory disease.
    Gómez-Puerta JA; Hernández-Rodríguez J; López-Soto A; Bosch X
    Chest; 2009 Oct; 136(4):1101-1111. PubMed ID: 19809051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biologic therapy in large and small vessels vasculitis, and Behçet's disease: Evidence- and practice-based guidance.
    Araújo Correia J; Crespo J; Alves G; Salvador F; Matos-Costa J; Alves JD; Fortuna J; Almeida I; Campar A; Brandão M; Faria R; Marado D; Oliveira S; Santos L; Silva F; Vasconcelos C; Fernandes M; Marinho A
    Autoimmun Rev; 2023 Aug; 22(8):103362. PubMed ID: 37230310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis.
    Slot MC; Tervaert JW; Boomsma MM; Stegeman CA
    Arthritis Rheum; 2004 Apr; 51(2):269-73. PubMed ID: 15077271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.